-+ 0.00%
-+ 0.00%
-+ 0.00%

Pyxis Oncology names Thomas Civik CEO, board chair

PUBT·09/08/2026 11:33:22
Listen to the news
Pyxis Oncology names Thomas Civik CEO, board chair
  • Pyxis Oncology named Thomas Civik chief executive officer, effective Sept. 4, 2026.
  • Civik also takes over as chairman; he had served as interim CEO since February 2026.
  • Co-founder John Flavin moved from chairman to lead independent director.
  • Civik previously led Five Prime Therapeutics until its $1.9 billion sale to Amgen in 2021.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Pyxis Oncology Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609080730PRIMZONEFULLFEED9822544) on September 08, 2026, and is solely responsible for the information contained therein.